Corcept Therapeutics (CORT) Tops Q3 EPS by 4c, Revenues Miss; Narrows FY20 Revenue Guidance Below Consensus
Go back to Corcept Therapeutics (CORT) Tops Q3 EPS by 4c, Revenues Miss; Narrows FY20 Revenue Guidance Below Consensus| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 114.69 +4.40 (3.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $110.29 | 52 Week High | $10.00 | |||
| Open | $110.29 | 52 Week Low | $3.22 | |||
| Day High | $116.65 | P/E | N/A | |||
| Day Low | $109.00 | EPS | $-0.46 | |||
| Volume | 575,761 | |||||
